|
|
||||||||
Howard Hughes Medical Institute, Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195
| Abstract |
|---|
|
|
|---|
expression. Dramatic enhancement of the selection efficiency is
observed, however, when fewer transgenic cells populate the thymus in
mixed bone marrow chimeras. These results suggest that positive
selection is limited by the availability of selecting peptides in the
thymus. This becomes apparent when large numbers of thymocytes compete
for such peptides in TCR transgenic animals. Under such conditions,
thymocytes appear to undergo further TCR
gene rearrangement to
produce a receptor that may be selected more efficiently by other
thymic self-peptides. | Introduction |
|---|
|
|
|---|
ß T cell lineage must pass through several
developmental checkpoints before they can mature into functional T
cells. To ensure the generation a diverse repertoire of T lymphocytes
that can effectively respond to a myriad of potential Ags, developing
thymocytes undergo random gene rearrangement at the TCR loci to produce
a unique receptor for each cell. Productive rearrangement of the TCR
ß-chain gene on one chromosome prevents further gene rearrangements
at the second TCRß allele and allows the initiation of TCR
gene
rearrangement (1). Allelic exclusion is not as tightly
controlled at the TCR
locus, however, resulting in some T cells that
express two
-chains paired with a common ß-chain on the cell
surface (2, 3, 4, 5, 6). Expression of a second TCR generally
occurs when the first receptor fails to interact with thymic self-MHC
molecules (7, 8, 9, 10, 11), which is required for cells to be
positively selected to mature (12).
Numerous studies have shown that positive selection of T cells is
critically dependent on the makeup of the endogenous peptide repertoire
expressed on thymic MHC molecules (reviewed in Ref. 13 and
14). Initial in vitro studies of positive selection of
class I MHC-restricted CD8+ T cells showed that
only specific peptides can promote the development of TCR transgenic T
cells in class I-deficient fetal thymic organ cultures
(15, 16, 17, 18). A similar requirement for peptide specificity
was shown for the selection of class II MHC-restricted
CD4+ T cells in studies analyzing thymocyte
development in mice expressing a severely reduced endogenous peptide
repertoire. H-2M° mice, for example, express predominantly the
invariant chain proteolytic fragment,
CLIP,3 on class II
molecules due to the inability to remove this peptide and allow
antigenic peptide binding (19, 20, 21, 22, 23, 24). Although a large
population of CD4+ T cells can still be selected
in these mice, the selected repertoire is incomplete and less diverse
in the types of TCR V
-J
joins used (25, 26, 27).
Moreover, our previous studies suggest that a large number of the
CD4+ T cells may be selected by the few
endogenous non-CLIP peptides displayed on class II molecules in H-2
M° mice (28). Finally, mice engineered to express a
single I-Ab binding peptide,
E
5258, on most class II molecules exhibit
normal selection of CD4+ T cells; however, when
crossed onto an H-2M° background, CD4+ T cell
development in these mice is severely diminished (29).
Thus, positive selection in this system occurs only when other
endogenous peptides can be loaded onto the small percentage of class II
molecules not occupied by the E
peptide.
These studies suggest that positive selection of a normal T cell repertoire requires a diverse array of endogenous peptides, including those that are expressed in relatively low abundance in the thymus. However, it is unclear whether the selection of T cells by self-peptides that are expressed at lower levels by thymic cortical epithelial cells is as efficient as selection mediated by more abundant peptides. Several studies suggest that this might not be the case, since they show that the number of thymocytes induced to undergo positive selection can be strongly influenced by the level of expression of MHC molecules (30, 31, 32, 33).
To explore this issue further, we have examined the development of
class II-restricted CD4+ T cells in three
different TCR transgenic mice carrying receptors selected on
I-Ab. Two of these mice, TEa and OT-II, have been
previously described (28, 34), whereas the third, TCli, is
a novel strain recently generated in our laboratory. Since TCR
transgenic mice provide a system where the thymus is saturated with
cells specific for the same selecting ligands, we could examine whether
the relative availability of selecting peptides for each TCR played an
important role in development. We found that positive selection of
thymocytes bearing the TCli TCR was significantly less efficient than
the selection of CD4+ T cells observed in the
other TCR transgenic mice. This was apparently due to thymocyte
competition for selecting peptides expressed in limited abundance in
the thymus. To compensate for this, thymocytes expressed an additional
receptor through secondary TCR
gene rearrangement, allowing positive
selection by other, more readily available thymic peptide:MHC
complexes.
| Materials and Methods |
|---|
|
|
|---|
Six- to 8-wk-old female C57BL/6J (B6,
H-2b) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and maintained at the animal facility at
the University of Washington. Recombinase activating gene-2
(RAG2)-deficient mice (H-2b) were purchased from
Taconic Farms (Germantown, NY). Invariant chain-deficient (Ii°) mice
(H-2b) were provided by Elizabeth Bikoff (Harvard
University, Boston, MA). H-2 M-deficient (H-2 M°) mice
(H-2b) were provided by Luc Van Kaer (Vanderbilt
University, Nashville, TN). OT-II/TCR
+ and
OT-II/TCR
° TCR transgenic mice were provided by Charles Surh (The
Scripps Research Institute, La Jolla, CA). TEa TCR transgenic mice were
generated as previously described (28) and were bred to
RAG2° mice for some experiments. Mutant and transgenic mice were bred
and maintained under specific pathogen-free conditions at the animal
facility at the University of Washington (Seattle, WA).
Generation of TCli TCR transgenic mice
The hCLIP:I-Ab-specific T cell hybridoma
51-11.5 was generated by immunizing H-2b mice
with hCLIP peptide (Ii81104) in CFA and
subsequently fusing activated lymph node cells with the
TCR
ß-negative BW5147 fusion partner (35). RT-PCR with
a panel of TCR V
-specific primers (provided by Pam Fink and Joan
Goverman, University of Washington) paired with a C
primer and
Vß-Cß primers indicated that this hybridoma uses V
18
(P14A.1)-J
45 and Vß6-Dß1-Jß2.2. PCR primers
(V
18+, 5'-TTC CCC GGG AAG AAT GCA CAG CCT CCT
AGG GTT G-3'; J
45-, 5'-CTT TGC CGC GGC TGT
AAT ACT TAC TTG GAG TCA C-3'; Vß6+, 5'-AAA GAA
ACT CGA GCC AAA CTA TGA ACA AGT GG-3'; Jß2.2-,
5'-TCC TCC CGC GGT ACC CCC AGC TGC CTG CTT ACC CAG CAC T-3') located 5'
and 3' of the relevant variable region leader and J region splice donor
sites were designed to amplify the rearranged TCR variable region
sequences from 51-11.5 genomic DNA and to introduce appropriate
restriction sites for insertion into the
XbaI-SacII or XhoI-SacII
cloning sites of the pT
and pTß genomic cassettes
(36), respectively (provided by Diane Mathis). The
expression and functionality of the TCR encoded by the resulting
genomic constructs were confirmed by their transfection into a TCR-loss
variant of the DO11.10 T cell hybridoma (a gift from Ann Pullen).
TCR
and TCRß constructs were coinjected into fertilized (B6
x DBA/2)F2 eggs, and a founder giving germline
transmission of both TCR
and TCRß transgenes was further crossed
onto B6 mice to establish the TCli TCR
ß transgenic line.
Construction of TCli TCRß transgenic mice involved injection of only
the TCRß construct. TCli TCR
ß transgenic mice were additionally
crossed onto the RAG2° background.
Radiation bone marrow chimeras
Bone marrow cells collected from the femurs and tibias of TCliRAG2+ or TCliRAG2° TCR transgenic or wild-type mice were washed in supplemented RPMI 1640 and depleted of T cells by treatment with a mixture of anti-CD4, anti-CD8 mAbs, and rabbit complement (Accurate Chemical & Scientific Corp., Westbury, NY). Cells were then washed several times in serum-free RPMI, and 5 x 106 cells were injected into the tail vein of each lethally irradiated (950 rad) recipient. Chimeras were given antibiotic-containing water and were healthy when analyzed 610 wk after bone marrow transfer.
Abs and peptides
The following mAbs directed to mouse cell surface Ags were
purchased from PharMingen (San Diego, CA): anti-CD4-PE
(RM4-5), anti-CD4-peridinin chlorophyll protein (RM4-5),
anti-CD8a-FITC (53-6.7), anti-CD8a-allophycocyanin
(53-6.7), anti-TCRß-PE (H57-597), anti-TCRß-biotin
(H57-597), anti-Vß6-biotin (RR4-7), anti-V
2-biotin (B20.1),
anti-V
3.2-biotin (RR3-16), anti-V
8-biotin (B21.14),
anti-V
11-biotin (RR8-1), anti-Ly- 9.1-FITC (30C7),
anti-Thy-1.1-FITC (HIS51), and anti-CD3 (145-2C11).
Biotin-coupled anti-TCR Vß Abs (Vß2-B20.6, Vß3-KJ25,
Vß4-KT4.1, Vß5-MR9-4, Vß6-RR4-7, Vß7-TR130, Vß8-F23.1,
Vß9-MR10-2, Vß10-B21.5, Vß11-RR3-15, Vß14-14.2) were provided
by Ann Pullen. Abs used for cell depletions were GK1.5 (anti-CD4,
American Type Culture Collection, Manassas, VA) and 53-6.72
(anti-CD8, American Type Culture Collection).
Anti-5-bromo-2-deoxyuridine (anti-BrdU)-FITC Ab was obtained from
Becton Dickinson (Mountain View, CA). All peptides were synthesized
with a Synergy 432 (Applied Biosystems, Foster City, CA) automated
peptide synthesizer using F-moc chemistry and analyzed by reverse phase
HPLC. The purity of peptides used was >90%.
Flow cytometry and BrdU labeling
In three-color analyses, approximately 5 x 105 cells were incubated on ice for 30 min with FITC-, PE-, and biotin-conjugated Abs; washed in PBS containing 1% FCS (Life Technologies, Grand Island, NY) and 0.1% sodium azide; and incubated with streptavidin-Tricolor (Caltag, San Francisco, CA) for an additional 30 min on ice. In four-color analyses, approximately 5 x 105 cells were incubated on ice for 30 min with PE-, peridinin chlorophyll protein-, allophycocyanin-, and biotin-conjugated Abs; washed in PBS containing 1% FCS (Life Technologies) and 0.1% sodium azide; and incubated with fluorescein-avidin D (Vector, Burlingame, CA) for an additional 30 min on ice. Labeled cells were washed and analyzed on a FACScan or FACScalibur flow cytometer (Becton Dickinson) using CellQuest and ReproMac software. For continuous BrdU labeling, BrdU (Sigma, St. Louis, MO) was dissolved in PBS at 0.8 mg/ml and given fresh daily to mice for a period of 14 days, after which mice were sacrificed, and their thymi were isolated for flow cytometric analysis.
T cell proliferation assays
For measurement of proliferative responses of peripheral T cells
from TCR transgenic mice, 4 x 105 pooled
lymph node cells were cultured per well with titrated amounts of CLIP
peptide in flat-bottom 96-well plates. T cell proliferation was
quantitated after 48 h of culture by pulsing cells with 1 µCi
[3H]thymidine/well for 20 h before
harvesting cells onto glass-fiber filters and determining incorporated
radioactivity using a BetaPlate liquid scintillation counter (Wallac,
Gaithersburg, MD). Results shown are expressed as mean counts per
minute of duplicate cultures. In some experiments, T cells were first
sorted on a FACStar Plus and plated at approximately 1 x
104 to 4 x 104/well
with approximately 5 x 105 irradiated
syngeneic B6 splenocytes plus peptide or Con A. Cells were pulsed with
1 µCi of [3H]thymidine/well after 48 h
of culture as described above. For analysis of endogenous TCR V
expression among TCli T cells after cognate peptide stimulation,
Ly-9.1+ TCli splenocytes were mixed with
wild-type Ly-9.1- B6 splenocytes at a 1/5 ratio
for a total of 2 x 106 cells/well in a
24-well plate and pulsed with either 0.2 µg/ml hCLIP or 5 µg/ml Con
A. After 7 days, cells were analyzed by flow cytometry. All cell
cultures were maintained in RPMI 1640 supplemented with 200 mM
L-glutamine, 10 mM HEPES, 5 x
10-5 M 2-ME, antibiotics
(penicillin-streptomycin), and 5% FCS at 37°C, 5%
CO2.
| Results |
|---|
|
|
|---|
To determine whether the efficiency of positive selection is
similar for TCRs specific for the same restriction element, we examined
CD4+ T cell development in three different lines
of TCR transgenic mice harboring receptors selected on
I-Ab. The TEa TCR
(Vß6+V
2+) recognizes
the E
5268 epitope derived from the class II
I-E
-chain, while the OT-II TCR
(Vß5+V
2+) is specific
for the OVA323339 peptide from chicken OVA,
both in the context of I-Ab (28, 34). We have also created a novel TCR transgenic mouse, TCli,
which carries a receptor specific for the human invariant chain-derived
CLIP peptide (hCLIP) in the context of I-Ab. TCli
mice express a V
18-J
45 TCR
-chain paired with a
Vß6-Dß1-Jß2.2 TCRß-chain cloned from the
hCLIP:I-Ab-specific T cell hybridoma 51-11.5
previously described (35). Similar to the TEa mice,
expression of the transgene is driven by the natural TCR
promoter/enhancer elements engineered in the pT
and pTß TCR
expression cassettes into which the TCli TCR was cloned
(36). T cells from the TCli mice exhibit uniformly high
Vß6 expression and strong proliferative responses to even small
amounts of hCLIP (Fig. 1
B and
data not shown).
|
|
ßTCR, we
crossed the transgenes onto RAG2° mice to prevent rearrangement of
endogenous TCR
-chain genes that could contribute to the expression
of nontransgenic receptors. Interestingly, although T cell development
was still skewed toward the
CD4+8- compartment, there
was a further reduction (>50%) in the percentage of CD4 SP thymocytes
in TCliRAG2° mice compared with that in RAG2+
transgenic littermates (Fig. 1
-chain expression was
abrogated. Flow cytometric analysis showed that the percentage of CD4
SP cells decreased only modestly in TEaRAG2° and OT-II/TCR
°
strains relative to that in their RAG2+ or
TCR
+ littermates, with a large percentage of
cells still able to transit efficiently from the DP to CD4 SP stage of
development (Fig. 2
The dramatic reduction in CD4+ T cell selection
in TCliRAG2° mice implied that a large proportion of the CD4 SP T
cells selected in the RAG-sufficient transgenics express endogenous
TCR
-chains paired with the transgenic ß-chain. To confirm this, we
assessed surface expression of other TCR
-chains in
TCliRAG2+ mice and could readily detect
CD4+ T cells expressing V
2, -3.2, -8, and -11
(Fig. 1
C). In contrast, we found very few cells bearing
endogenous TCR V
3.2, -8, and -11 among CD4+ T
cells of TEa and OT-II mice (Fig. 1
C and data not
shown).
Expression of both endogenous and transgenic TCR
-chains on the
majority of TCli T cells
Several studies have shown that TCR
ß-expressing thymocytes
that fail to be positively selected can undergo further TCR
gene
rearrangement to produce a selectable TCR, thereby expressing two
TCR
-chains on the cell surface (7, 8, 10, 37). Since
the TCli TCR is selected relatively poorly, we reasoned that the
prevalent endogenous
-chain usage might reflect dual TCR
expression as a means of improving selection efficiency. Alternatively,
poor expression of the transgenic TCR
-chain could result in large
numbers of T cells that express only endogenous TCR
-chains. To
exclude the latter possibility, we assessed whether the endogenous
TCR
expression observed in TCliRAG2+ mice
reflected prominent dual TCR
expression on transgenic T cells.
Without an anti-clonotypic or anti-V
18 Ab, we were unable to
determine directly whether endogenous and transgenic TCR
-chains were
coexpressed on the same cells or expressed on distinct cell
populations. To examine this in an alternative fashion, we
compared the ability of CD4+ T cells from
TCliRAG2° and TCliRAG2+ mice to respond to
cognate Ag. If nontransgenic and transgenic
-chains were expressed
on different populations of cells, then we would expect
TCliRAG2+ cells to give a lower proliferative
response to hCLIP than TCliRAG2° cells in an assay in which
equivalent numbers of CD4+ T cells were analyzed.
This would be due to the large proportion of nonresponding, endogenous
TCR
-bearing CD4+ T cells in the
TCliRAG2+ mice.
When CD4+ T cells isolated from
TCliRAG2+ and TCliRAG2° mice were stimulated
with peptide-pulsed, irradiated, syngeneic, wild-type B6 splenocytes, a
similar degree of proliferation to hCLIP by the two responding
populations was observed (Fig. 3
A). Comparable responses to
hCLIP were also observed in assays where the responder
CD4+ T cells from TCliRAG2+
and TCliRAG2° mice were titrated from 4 x
104 to 1 x 104
cells/well (not shown). This strongly suggested that although many
TCliRAG2+ T cells express endogenous
-chains, these cells coexpress the hCLIP-responsive TCli
TCR
ß.
|
-bearing transgenic
T cells also express a functional TCli TCR
-chain on the surface, we
sorted V
2+CD4+ T cells
from TCliRAG2+ mice and assessed their ability to
respond to hCLIP. We found that
V
2+CD4+ T cells from
TCliRAG2+ mice responded to the cognate peptide
almost as strongly as the same number of CD4+ T
cells from TCliRAG2° animals carrying solely the transgenic TCR (Fig. 3
-chain that competes for pairing with the
TCliß-chain. However, one might also argue that pairing of the TCli
TCRß-chain with an endogenous TCR
-chain could bias cells toward
hCLIP reactivity. Indeed, in some experimental systems TCR specificity
is dictated in large part by the TCRß-chain. For example,
CD8+ T cells expressing only the ß-chain of the
chicken OVA peptide:Kb-specific TCR or
CD4+ T cells expressing only the ß-chain of the
TCR specific for the myelin basic protein epitope,
Ac116, presented by I-Au
can mount significant responses to their cognate peptides (38, 39). To exclude this possibility, we also sorted
V
2+CD4+ T cells from
mice that were transgenic for the TCli TCRß-chain alone. When these
cells were cultured with hCLIP, we were unable to detect any
significant proliferative response (Fig. 3
-bearing T cells from
TCliRAG2+ TCR
ß transgenic mice requires
coexpression of the TCli TCR
-chain.
Coexpression of both transgenic and endogenous TCR
-chains on the
surface of TCliRAG2+ T cells was further
confirmed by the analysis of TCR
-chain expression among TCli T cells
expanded in vitro with the cognate peptide.
TCliRAG2+ splenocytes bearing the Ly-9.1 marker
were mixed with normal Ly-9.1- B6 splenocytes at
a 1/5 ratio, stimulated in vitro with either hCLIP or Con A, and
analyzed after 7 days. Selective expansion of transgenic
CD4+ and Vß6+ T cells
upon stimulation with hCLIP, but not with Con A, indicated an Ag-driven
selection for specific T cells (Fig. 4
A). However, analysis of
endogenous V
usage before and after stimulation indicated no
significant change in the percentage of transgenic
CD4+ T cells expressing endogenous V
2, -3.2,
-8, or -11 after 1 wk in culture with specific peptide (Fig. 4
B). These cells would be expected to decrease significantly
after antigenic stimulation if they represented a population distinct
from the Vß6+V
18+ TCli
transgenic T cells. Instead, the results are consistent with endogenous
TCRs being coexpressed with the responding TCli TCR on the same cells.
Moreover, these endogenous receptors appear to be neither selected for
nor against during the Ag-specific response in the periphery,
indicating that they more likely play a role in positive selection in
the thymus.
|
Dual TCR
-chain expression among TCliRAG2+
transgenic thymocytes may confer an advantage during positive selection
in the thymus by providing developing cells an additional receptor and
thus a broader range of thymic peptides that might serve as positively
selecting ligands. To show that positive selection occurs more
efficiently among transgenic thymocytes that can express endogenous
TCR
-chains on the surface, we analyzed the rate of development
of mature CD4 SP T cells in TCliRAG2+ vs
TCliRAG2° mice, using the thymidine analogue BrdU. Dividing
thymocytes that incorporate BrdU can be tracked using an anti-BrdU
Ab by flow cytometry. Mice were continuously labeled with BrdU in
drinking water for a period of 14 days and were analyzed by FACS for
the accumulation of labeled CD3high
CD4+ thymocytes over time. We found that the
accumulation of labeled mature CD4 SP thymocytes was significantly
delayed, by approximately 1 day, in TCliRAG2° mice compared with
TCliRAG2+ mice (Fig. 5
). Thus, the absence of endogenous
TCR
-chain expression decreases the rate of
CD4+ T cell development in TCli mice.
|
We hypothesized that the inefficiency of selection of the TCli TCR
could be explained by highly selective self-peptide recognition during
positive selection and competition for limited selecting peptide:MHC
ligand(s) present in the thymus. To test this, we transferred TCli bone
marrow into lethally irradiated Ii° and H-2 M° mice, which exhibit
much reduced class II peptide diversity (22, 23, 24, 28, 40, 41, 42, 43, 44, 45). As predicted, TCli
B6 chimeras showed normal
development of transgenic CD4+ T cells, but
TCli
Ii° and TCli
H-2 M° chimeras exhibited almost complete
abrogation of CD4+ T cell selection (Fig. 6
). These results demonstrate the high
degree of peptide selectivity involved in positive selection of the
TCli TCR.
|
|
| Discussion |
|---|
|
|
|---|
paired with the transgenic
TCRß-chain. In the absence of RAG2, thymocyte development is markedly
reduced in TCli mice such that very little difference in
CD4+ T cell selection is observed between
transgenic and nontransgenic littermates (Fig. 1It has been realized for some time that positive selection in TCR transgenic animals is not 100% efficient, even though all developing thymocytes express a receptor capable of being positively selected. For example, it has been shown that only about 20% of the DP thymocytes in H-Y TCR transgenic mice mature to the SP stage, and that optimal selection efficiency is obtained only when transgenic cells are reduced to approximately 5% or less of all CD4+8+ cells (46). This was explained by a lack of appropriate selecting niches in the thymus to support the development of every transgenic thymocyte (33, 47).
It has been unclear, however, what such selecting niches represent. They may refer to a specialized subset of cortical epithelial cells that can be accessed by developing thymocytes, particular microdomains enriched in specific soluble growth or differentiation factors, or specific TCR ligands. However, limited thymocyte-epithelial cell contact or lack of certain microenvironments or factors cannot explain the large differences in selection efficiencies observed among the TCli, TEa, and OT-II TCR transgenic mice or the differences in selection between TCliRAG2+ and TCliRAG2° animals.
Our results suggest that the selecting niches for a given TCR are
simply the specific self-peptide:MHC complexes that can mediate its
positive selection, and their availability largely determines the
efficiency of T cell development. Since different self-peptides are
expressed at different levels of abundance in the thymus, this may
account for the differences in selection observed for different TCR
transgenic mice. For the TCli TCR, competition by many transgenic
thymocytes for selecting peptides that are expressed in relatively low
abundance on thymic class II molecules leads to inefficient positive
selection. This would explain how the selection efficiency can be
dramatically enhanced by decreasing the proportion of TCli precursors
in the thymus. Compared with TCli mice, TEa and OT-II TCR transgenic
mice exhibit significantly better selection efficiencies (Fig. 2
), most
likely because the specific selecting peptides for these two receptors
may be more abundant. Since the TEa mice were constructed with the
identical TCR
and TCRß expression constructs used for generating
the TCli mice (28), it is unlikely that differences in
transgene expression could account for the different selection
efficiencies. TCR-specific differences in selection efficiency have
also been reported for three different lines of transgenic mice
carrying structurally similar TCRs specific for a cytochrome
c peptide bound to I-Ek
(31). These differences were attributed to differences in
the selecting niches used by each receptor; some TCRs appeared to
require highly specific peptide ligands that became limiting at low
doses of the selecting MHC, while other TCRs appeared to be more
peptide-promiscuous in their selection requirements. Alternatively, the
different TCRs may have different affinities for selecting ligand. Our
results further extend the idea set forth by these previous studies
that different TCRs can be selected with different efficiencies
depending on the abundance of or affinity for the selecting
ligand(s).
In our study, however, it is unlikely that TCR affinity for the selecting ligand plays a major role in the results observed. If the weak selection of TCli thymocytes were due to a lower affinity of the TCli TCR for the positively selecting ligand compared with that of the TEa or OT-II TCRs, we would not expect to see the dramatic increase in CD4 SP selection when the number of TCli TCR transgenic precursors is reduced in mixed bone marrow chimeras. Nevertheless, we cannot formally exclude the possibility that the TCli TCR-selecting ligand interaction is of low affinity and that perhaps the selecting niche for which the TCli thymocytes compete is a rare specialized cortical epithelial cell that may provide certain accessory molecules that enhance less avid TCR-peptide-MHC interactions and thereby promote more efficient selection of TCli thymocytes. Since such a subset of thymic epithelial cells has not been previously documented, and the selecting ligands for the TCRs analyzed here are not known, this possibility is difficult to address.
It has been suggested that CD5 expression levels on mature SP thymocytes reflect the avidity of the positively selecting TCR-peptide interaction (48). We have observed no difference in CD5 expression on TCli and TEa CD4 SP thymocytes (P. Wong, unpublished observations). Instead, we have actually found that expression of this marker on TCR transgenic DP thymocytes is uniformly high and appears to be proportional to the endogenous peptide diversity on thymic class II molecules, but does not correlate with positive selection efficiency (P. Wong et al., manuscript in preparation). Thus, although we cannot rule out the possibility that TCR affinity for selecting ligand can explain the difference in selection efficiencies shown in this study, it is an unlikely explanation. Based on our data, it is more likely that levels of specific selecting peptides play a major role in selection efficiency differences between individual receptors.
Further evidence for the highly selective nature of the peptide
recognition events that allow TCli thymocytes to mature is the finding
that the TCli TCR is not selected in either the Ii° or H-2 M°
thymic environments where the endogenous peptide repertoire is
drastically reduced. It was especially interesting to discover in bone
marrow chimeras that even the closely related, endogenous mCLIP peptide
expressed abundantly in H-2 M° mice was unable to promote the
development of the hCLIP-specific TCli T cells (Fig. 6
). We confirmed
this finding in TCli fetal thymic organ culture studies in which
CLIP:I-Ab complex-specific Abs failed to inhibit
positive selection of transgenic T cells (data not shown). This is
consistent with recent studies suggesting that the selecting peptides
for a given T cell may not necessarily resemble the peptides that
activate it in the periphery (49, 50). Since we have
previously shown that mCLIP is a fairly well represented self-peptide
in a normal thymus (51), its inability to select the TCli
TCR is perhaps not surprising given that our data suggest that
selection of the TCli TCR is probably mediated by peptides expressed in
limiting amounts.
How do developing TCli thymocytes cope with the paucity of selecting
peptide ligands? From our results, it appears that when they express a
second TCR, the TCli thymocytes have an improved chance at positive
selection. Dual TCR
-chain expression has been observed in other TCR
transgenic as well as nontransgenic T cells and has been correlated
with inefficient positive selection of the initially expressed TCR
(2, 3, 4, 5, 7, 8, 10, 37). Endogenous TCRß expression has
also been reported in one TCR transgenic mouse exhibiting weak positive
selection (32), but this may be transgene specific, and we
have not observed this in the TCli mice. In support of ligand
availability as a critical factor in positive selection, it was also
found in that report that decreased levels of the selecting MHC
molecules resulted in inefficient development of transgenic
TCR-expressing T cells and increased endogenous TCR usage
(32). Our results are consistent with and further extend
these previous studies, since we observe less endogenous TCR
expression in TEa and OT-II TCR transgenic mice where
CD4+ T cell selection is more efficient. In
addition, positive selection is not decreased as dramatically in these
latter mice in the absence of RAG2, indicating that the majority of
CD4+ T cells are selected through the transgenic
TCR. In contrast, the high frequency of cells bearing endogenous
TCR
-chains in TCliRAG2+ mice suggests that
selection through the TCli TCR is relatively poor. By expressing a
second receptor, TCli thymocytes are able to sample other peptide:MHC
ligands that may be more readily available than those for the TCli TCR
and become positively selected through endogenous TCR-peptide:MHC
interactions. Thus, prevalent endogenous TCR
-chain usage among the
poorly selected TCli thymocytes as a mechanism for increasing
CD4+ T cell development is another indication
that specific peptide:MHC complex availability is a rate-limiting
factor for efficient positive selection.
Since the relative availability of different self-peptides in the thymus plays a critical role in shaping the T cell repertoire, it is interesting to speculate whether peptides expressed in low abundance on thymic cortical epithelial cells have more favorable interactions with cells bearing high affinity TCRs and thereby promote their development. This is again difficult to address, since we do not know what the selecting peptide is for the TCli TCR or what the affinity of the TCli TCR is for its selecting ligand. However, preliminary affinity measurements of the TCli TCR for the hCLIP:I-Ab complex suggest that this receptor binds to its cognate ligand in the periphery very strongly, with a Ka of approximately 109 M-1 (L. Teyton, C. Cantu III, and P. Wong, unpublished observations). This is about 3 orders of magnitude higher than the affinities reported to date for peptide:MHC/TCR interactions and is similar to the affinity measured for the 30-2 mAb specific for the hCLIP:I-Ab complex. It will be interesting to determine whether thymic self-peptides present in limiting amounts select for high affinity receptors.
We conclude that peptide specificity is a crucial component of positive selection, but equally important is the accessibility of those peptides to the developing T cell repertoire. Low level expression of the peptides critical for the selection of an individual thymocyte may reduce the efficiency of its development. Inefficient selection through the initially expressed receptor can induce the expression of a second TCR as thymocytes attempt to produce a selectable receptor. Since it is entirely possible that the initially expressed TCR can be positively selected under more abundant ligand conditions, positive selection on the second receptor may allow the development of cells that express two functional self-restricted TCRs in the periphery.
| Acknowledgments |
|---|
and pTß TCR
expression cassettes; Ann Pullen for Ab reagents; and Charles Surh,
Frank Carbone, and Bill Heath for the OT-II TCR transgenic
mice. | Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Alexander Rudensky, Box 357370, Howard Hughes Medical Institute, Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195. ![]()
3 Abbreviations used in this paper: CLIP, class II-associated invariant chain peptide; hCLIP, human CLIP; mCLIP, murine CLIP; Ii, invariant chain; Ii°, Ii deficient; H-2 M°, H-2 M deficient; BrdU, 5-bromo-2-deoxyuridine; RAG, recombinase-activating gene; RAG2°, RAG deficient; SP, single positive; DP, double positive. ![]()
Received for publication January 21, 2000. Accepted for publication April 10, 2000.
| References |
|---|
|
|
|---|
-gene rearrangements found in both the A10 and BM 3.3 T cell clones give rise to an
chain which can contribute to the constitution of a surface-expressed
ß dimer. Int. Immunol. 3:719.
chains: dual receptor T cells. Science 262:422.
chains on the surface of T cells in T cell receptor transgenic mice. J. Exp. Med. 178:1807.
chains on the surface of normal murine T cells. Eur. J. Immunol. 25:1617.[Medline]
chain T cells in autoimmunity. J. Exp. Med. 182:953.
T cells. Eur. J. Immunol. 28:2115.[Medline]
and ß T cell receptor alleles. Cell 69:529.[Medline]
ß dimers and facilitates peptide loading. Cell 82:155.[Medline]
- and ß-chains is highly dependent on the level of selecting ligand. J. Immunol. 161:585.
- and ß-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76:34.[Medline]
chain genes maximize the production of useful thymocytes. J. Exp. Med. 178:615.This article has been cited by other articles:
![]() |
D. C. Jay, L. M. Reed-Loisel, and P. E. Jensen Polyclonal MHC Ib-Restricted CD8+ T Cells Undergo Homeostatic Expansion in the Absence of Conventional MHC-Restricted T Cells J. Immunol., March 1, 2008; 180(5): 2805 - 2814. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Haring, L. L. Pewe, and S. Perlman Bystander CD8 T Cell-Mediated Demyelination After Viral Infection of the Central Nervous System J. Immunol., August 1, 2002; 169(3): 1550 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Honey, T. Nakagawa, C. Peters, and A. Rudensky Cathepsin L Regulates CD4+ T Cell Selection Independently of Its Effect on Invariant Chain: A Role in the Generation of Positively Selecting Peptide Ligands J. Exp. Med., May 20, 2002; 195(10): 1349 - 1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kirchner, K. A. Forbush, and M. J. Bevan Identification and Characterization of Thymus LIM Protein: Targeted Disruption Reduces Thymus Cellularity Mol. Cell. Biol., December 15, 2001; 21(24): 8592 - 8604. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wong, G. M. Barton, K. A. Forbush, and A. Y. Rudensky Dynamic Tuning of T Cell Reactivity by Self-Peptide-Major Histocompatibility Complex Ligands J. Exp. Med., May 21, 2001; 193(10): 1179 - 1188. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |